Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present 18 abstracts, ...

A Phase I first-in-human dose escalation study to test it under the name BAY 3713372 in MTAP-deleted solid tumors has already begun with the enrollment of the first patient. “We are looking ...

"We are looking forward to exploring the potential of the PRMT5 inhibitor, which could improve outcomes for patients with MTAP-deleted tumors who often have a poor prognosis," said Juergen ...

Bayer said on Wednesday it struck a global licence agreement for an experimental oral cancer drug for targeted therapies with China's Puhe BioPharma.

Initiated Phase 1/2 study expansion for IDE397, IDEAYA's MAT2A inhibitor, in combination with Trodelvy ®, Gilead's Trop-2 directed ADC, in MTAP-deletion urothelial cancer based on preliminary ...

Bayer and Suzhou Puhe BioPharma Co.,Ltd., a clinical-stage biotechnology company, announced that they have entered into a global license agreement for Puhe BioPharma’s oral, small molecule PRMT5 ...

IDE397 is a potent and selective small molecule inhibitor targeting (MAT2A), in patients having solid tumors with MTAP-deletion. The prevalence of MTAP-deletion is estimated to be approximately 26 ...

IDE397 is a potent and selective small molecule inhibitor targeting (MAT2A), in patients having solid tumors with MTAP-deletion. The prevalence of MTAP-deletion is estimated to be approximately 26% in ...

SOUTH SAN FRANCISCO, Calif., April 10, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted ...

SOUTH SAN FRANCISCO, Calif., April 10, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted ...